<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02125032</url>
  </required_header>
  <id_info>
    <org_study_id>T-PEMF14</org_study_id>
    <secondary_id>CIV-14-01-011780</secondary_id>
    <nct_id>NCT02125032</nct_id>
  </id_info>
  <brief_title>Transcranial Low Voltage Pulsed Electromagnetic Fields (T-PEMF) in Patients With Parkinson's Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <brief_summary>
    <textblock>
      The aim of this study, is to determine whether treatment using transcranial low voltage&#xD;
      pulsed electromagnetic fields (T-PEMF) can reduce the symptoms patients with Parkinson's&#xD;
      Disease (PD) experience. The symptoms include movement, mentality and the nervous system in&#xD;
      general.&#xD;
&#xD;
      Furthermore the purpose of this study is to clarify whether a group of patients with PD, gain&#xD;
      a statistical improvement in their symptoms when treated with active T-PEMF, compared to a&#xD;
      group of patients with PD who receive placebo T-PEMF .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Unified ParkinsonÂ´s Disease Rating Scale (UPDRS)</measure>
    <time_frame>At baseline and at endpoint at week 8.</time_frame>
    <description>Comment on &quot;Title&quot;: It is expected that the outcome measure UPDRS will report a change after 8 weeks of treatment compared to baseline.&#xD;
Comment on &quot;Time Frame&quot;: Data will be assessed at each group after 8 weeks, and will be presented when all included patients have received their intervention.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Transcranial pulsed electromagnetic fields (T-PEMF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One group receives 8 weeks of active T-PEMF treatment and another group receives 8 weeks of placebo T-PEMF. Both treatments to be performed 30 minutes once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trancranial electromagnetic pulsed fields (T-PEMF)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 weeks of T-PEMF treatment placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial low voltage pulsed electromagnetic fields (T-PEMF)</intervention_name>
    <arm_group_label>Transcranial pulsed electromagnetic fields (T-PEMF)</arm_group_label>
    <other_name>The device name is: Re5 - Parkinson Treatment System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo Transcranial low voltage electromagnetic fields</intervention_name>
    <arm_group_label>Trancranial electromagnetic pulsed fields (T-PEMF)</arm_group_label>
    <other_name>The devise name is: Re5 - Parkinson Treatment System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Idiopathic Parkinson's disease H &amp; Y 1-3 (Hoehn&amp;Yahr)&#xD;
&#xD;
          -  MMSE &gt; 22 (a screening test for dementia). (MMSE - Mini-Mental State Examination)&#xD;
&#xD;
          -  Age &gt; 18 years.&#xD;
&#xD;
          -  The patient is capable understanding, accepting and complete the planned procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has been using T-PEMF before.&#xD;
&#xD;
          -  Changes in anti-parkinson drug treatment within the last 6 weeks&#xD;
&#xD;
          -  Noticeable dementia or other brain injury, which may affect the ability to give&#xD;
             consent, or complicates the assessment of the patient&#xD;
&#xD;
          -  Psychosis, or other psychopathological conditions, which requires intervention&#xD;
&#xD;
          -  The abuse of alcohol or drugs&#xD;
&#xD;
          -  Treatment with Deep Brain stimulation.&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  Epilepsy.&#xD;
&#xD;
          -  Active implants such as pacemakers and others for example cochlear implants&#xD;
&#xD;
          -  Active medical device for example insulin pumps, baclofen pumps.&#xD;
&#xD;
          -  Participation in other trials in the intervention period&#xD;
&#xD;
          -  Current or previous history of brain tumors, leukemia, malignant melanoma, skin&#xD;
             cancer, or head and neck cancer&#xD;
&#xD;
          -  Autoimmune disease&#xD;
&#xD;
          -  Wounds in the scalp&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>OUH Odense University Hospital</name>
      <address>
        <city>Odense C</city>
        <state>Funen</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 23, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2014</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Bo Mohr Morberg</investigator_full_name>
    <investigator_title>MD, Ph.D. student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

